Race against time: can new drugs slow scarring of the lungs?
NCT ID NCT05497284
Summary
This study aimed to test whether new investigational drugs could slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Adults with IPF were randomly assigned to receive either an experimental treatment or a placebo for 26 weeks to see if it could help preserve their lung function and quality of life. The trial was terminated early by the sponsor for strategic reasons before any definitive conclusions could be reached.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
CABA, Buenos Aires, C1056ABJ, Argentina
-
Novartis Investigative Site
Ranelagh Partido de Berazate, Buenos Aires, 1884, Argentina
-
Novartis Investigative Site
Paraná, 3100, Argentina
-
Novartis Investigative Site
Camperdown, New South Wales, 2050, Australia
-
Novartis Investigative Site
Chermside, Queensland, 4032, Australia
-
Novartis Investigative Site
Spearwood, Western Australia, 6163, Australia
-
Novartis Investigative Site
Prague, 140 59, Czechia
-
Novartis Investigative Site
Munich, Bavaria, 81377, Germany
-
Novartis Investigative Site
Coswig, 01640, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Amsterdam, North Holland, 1081 HV, Netherlands
-
Novartis Investigative Site
Nieuwegein, Utrecht, 3435 CM, Netherlands
-
Novartis Investigative Site
Bialystok, 15-044, Poland
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Kansas Hospital
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.